ADVI Analysis: The Colorado Prescription Drug Affordability Meeting

Pharmaceuticals and Biotech State Policy Federal And State Policy Pharmaceuticals and Biotech

December 11, 2023

On December 7, 2023, the Colorado Prescription Drug Affordability Board (PDAB) held a meeting to vote on Trikafta’s affordability, and review Genvoya and Enbrel’s affordability review data (link).

ADVI Angle

Summary

  • The Board reviewed voted unanimously (5-0) to determine Trikafta is not unaffordable.
    • “The use of Trikafta, consistent with the labeling approved by the FDA or with standard medical practice, is not unaffordable for Colorado consumers.”
      • Board discussion around Trikafta’s affordability was centered on the drug’s real-world evidence of clinical benefit, along with patient testimony. Board members were also in agreement that Trikafta is currently largely affordable due to Vertex’s patient assistance program.
    • Notably, the Board’s vote that Trikafta is affordable means that the PDAB cannot move forward with setting an upper payment limit (UPL) for the drug.
  • The Board was in agreement that there is still concern, as a whole, regarding the cost of Trikafta, and that they are in favor of taking another look at this drug for future affordability reviews if they begin to hear from the Cystic Fibrosis community that it is no longer affordable.
  • The next scheduled meeting is with the Prescription Drug Affordability Advisory Council, and will be held on January 25, 2024.

This is an abridged and delayed release. Full ADVI Analysis content is distributed in real time for retainer clients. Get in touch to learn more about how we can support your commercialization, market access, and policy needs.


CEO insights

Real analysis from people who’ve been there

Medicare Negotiation Program Deselection: Analysis of Previously Deselected Drugs and Likely Fall 2026 Targets

Authored by Allison Schneider, MHA, and Lindsay Bealor Greenleaf, JD, MBA Under the Inflation Reduction Act, drugs selected for the …

November 4, 2026

Health Policy & Access Strategy Inflation Reduction Act

Exclusive Webinar: Unpacking the Future of U.S. Drug Pricing Policy

Gain immediate access to actionable insights from CMS and ADVI Health policy leaders. From the Medicare Drug Price Negotiation Program …

October 2, 2026

Health Policy & Access Strategy Inflation Reduction Act

Analysis of 340B modifier usage in Medicare Part B claims

Analysis of Part B Claims from January 2025 through June 2026 Prepared By:Johanna Celli, Pete Kardel, Caitlin Sheetz, ADVI Health’s …

September 30, 2026

Precision Medicine

CMS Proposes RAPID Coverage Pathway for Breakthrough Devices

IVDs remain outside scope, while FDA-CMS Parallel Review remains available. KEY TAKEAWAY RAPID could materially shorten the gap between Food …

August 21, 2026

Cell and Gene Precision Medicine State Policy

The 2026 Rare Disease Reality

Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …

Marc Samuels, JD, MPH
February 26, 2026

AI in the Patient Care Paradigm: Examining Regulatory Challenges to Clinical Adoption  

Artificial intelligence could transform clinical care, but regulatory hurdles slow adoption. Ensuring healthcare AI has adequate policy safeguards is paramount …

Marc Samuels, JD, MPH
December 30, 2025

Precision Medicine

2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption

In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …

Marc Samuels, JD, MPH
December 16, 2025

Cell and Gene

Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care

CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …

Alicia Silver, MPP
November 21, 2025

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.